Abstract
Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.
| Original language | English |
|---|---|
| Pages (from-to) | 341-346 |
| Number of pages | 6 |
| Journal | International Journal of Cancer |
| Volume | 56 |
| Issue number | 3 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Expression of gp185(HER-2) in human cutaneous melanoma : Implications for experimental immunotherapeutics. / Natali, P. G.; Nicotra, M. R.; Digiesi, G.; Cavaliere, R.; Bigotti, A.; Trizio, D.; Segatto, O.
In: International Journal of Cancer, Vol. 56, No. 3, 1994, p. 341-346.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Expression of gp185(HER-2) in human cutaneous melanoma
T2 - Implications for experimental immunotherapeutics
AU - Natali, P. G.
AU - Nicotra, M. R.
AU - Digiesi, G.
AU - Cavaliere, R.
AU - Bigotti, A.
AU - Trizio, D.
AU - Segatto, O.
PY - 1994
Y1 - 1994
N2 - Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.
AB - Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0028179151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028179151&partnerID=8YFLogxK
M3 - Article
C2 - 7906252
AN - SCOPUS:0028179151
VL - 56
SP - 341
EP - 346
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 3
ER -